Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

177 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Preliminary results for avelumab plus axitinib as first-line therapy in patients with advanced clear-cell renal-cell carcinoma (JAVELIN Renal 100): an open-label, dose-finding and dose-expansion, phase 1b trial.
Choueiri TK, Larkin J, Oya M, Thistlethwaite F, Martignoni M, Nathan P, Powles T, McDermott D, Robbins PB, Chism DD, Cho D, Atkins MB, Gordon MS, Gupta S, Uemura H, Tomita Y, Compagnoni A, Fowst C, di Pietro A, Rini BI. Choueiri TK, et al. Among authors: martignoni m. Lancet Oncol. 2018 Apr;19(4):451-460. doi: 10.1016/S1470-2045(18)30107-4. Epub 2018 Mar 9. Lancet Oncol. 2018. PMID: 29530667 Clinical Trial.
Avelumab Plus Axitinib as First-Line Therapy for Advanced Renal Cell Carcinoma: Long-Term Results from the JAVELIN Renal 100 Phase Ib Trial.
Larkin J, Oya M, Martignoni M, Thistlethwaite F, Nathan P, Ornstein MC, Powles T, Beckermann KE, Balar AV, McDermott D, Gupta S, Philips GK, Gordon MS, Uemura H, Tomita Y, Wang J, Michelon E, di Pietro A, Choueiri TK. Larkin J, et al. Among authors: martignoni m. Oncologist. 2023 Apr 6;28(4):333-340. doi: 10.1093/oncolo/oyac243. Oncologist. 2023. PMID: 36576173 Free PMC article. Clinical Trial.
A retrospective, multicentric, nationwide analysis of the impact of splenectomy on survival of pancreatic cancer patients.
Kießler M, Jäger C, Mota Reyes C, Pergolini I, Schorn S, Göß R, Safak O, Martignoni ME, Novotny AR, Uhl W, Werner J, Ghadimi M, Hartwig W, Ruppert R, Keck T, Bruns CJ, Oldhafer KJ, Schnitzbauer A, Germer CT, Sommer F, Mees ST, Brunner M, Köninger J, Glowka TR, Kalff JC, Reißfelder C, Bartsch DK, Kraus T, Padberg W, Piso P, Lammers BJ, Rudolph H, Moench C, Farkas S, Friess H, Ceyhan GO, Demir IE. Kießler M, et al. Among authors: martignoni me. Langenbecks Arch Surg. 2024 Dec 22;410(1):14. doi: 10.1007/s00423-024-03570-y. Langenbecks Arch Surg. 2024. PMID: 39710775 Free PMC article.
Inter-organ cross-talk in human cancer cachexia revealed by spatial metabolomics.
Sun N, Krauss T, Seeliger C, Kunzke T, Stöckl B, Feuchtinger A, Zhang C, Voss A, Heisz S, Prokopchuk O, Martignoni ME, Janssen KP, Claussnitzer M, Hauner H, Walch A. Sun N, et al. Among authors: martignoni me. Metabolism. 2024 Dec;161:156034. doi: 10.1016/j.metabol.2024.156034. Epub 2024 Sep 17. Metabolism. 2024. PMID: 39299512 Free article.
ARX, PDX1, ISL1, and CDX2 Expression Distinguishes 5 Subgroups of Pancreatic Neuroendocrine Tumors With Correlations to Histology, Hormone Expression, and Outcome.
Moser E, Ura A, Vogel L, Steiger K, Mogler C, Evert M, Märkl B, Scheidhauer K, Martignoni M, Friess H, von Werder A, Marinoni I, Perren A, Klöppel G, Kasajima A. Moser E, et al. Among authors: martignoni m. Mod Pathol. 2024 Nov;37(11):100595. doi: 10.1016/j.modpat.2024.100595. Epub 2024 Aug 13. Mod Pathol. 2024. PMID: 39147030 Free article.
177 results